Clinical Trial Update: A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Phase 4]

View source ↗

Summary

Pfizer completed a Phase 4 study evaluating the safety and efficacy of tafamidis in Chinese participants with transthyretin amyloid cardiomyopathy; results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin Amyloid Cardiomyopathy | Phase 4 | Status: COMPLETED | Results posted: 2024-12-18